LPL Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

LPL Financial’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.91M	Sell	111,150 -8,231	-7%	-$192K	﹤0.01%	3327
2026 Q1	$2.81M	Buy	119,381 +7,507	+7%	+$192K	﹤0.01%	3188
2025 Q4	$3.25M	Sell	111,874 -5,050	-4%	-$129K	﹤0.01%	2930
2025 Q3	$2.2M	Sell	116,924 -4,693	-4%	-$74K	﹤0.01%	3227
2025 Q2	$1.71M	Buy	121,617 +5,860	+5%	+$82.2K	﹤0.01%	3275
2025 Q1	$1.81M	Sell	115,757 -5,135	-4%	-$72.3K	﹤0.01%	3037
2024 Q4	$1.68M	Sell	120,892 -5,388	-4%	-$59K	﹤0.01%	3027
2024 Q3	$1.17M	Sell	126,280 -23,260	-16%	-$230K	﹤0.01%	3240
2024 Q2	$1.39M	Sell	149,540 -8,665	-5%	-$78.4K	﹤0.01%	2943
2024 Q1	$1.57M	Sell	158,205 -31,438	-17%	-$235K	﹤0.01%	2766
2023 Q4	$613K	Buy	189,643 +106,130	+127%	+$289K	﹤0.01%	3505
2023 Q3	$443K	Buy	83,513 +48,931	+141%	+$416K	﹤0.01%	3587
2023 Q2	$330K	Buy	+34,582	New	+$384K	﹤0.01%	3770

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

LPL Financial's ARQT Position: Q2 2026 in Review

LPL Financial reduced its Arcutis Biotherapeutics (ARQT) stake by 6.9% in Q2 2026, selling an estimated $192K and leaving 111,150 shares worth $2.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3327.

LPL Financial first reported a position in ARQT in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.25M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

LPL Financial held 111,150 shares of Arcutis Biotherapeutics worth $2.91M as of Q2 2026.
LPL Financial sold 8,231 Arcutis Biotherapeutics shares in Q2 2026, an estimated $192K.
Arcutis Biotherapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #3327 holding.
LPL Financial first reported a position in Arcutis Biotherapeutics in Q2 2023 and has held it in 13 quarters since.
LPL Financial's Arcutis Biotherapeutics position peaked at $3.25M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.